Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,592.53
(
-0.49%
)
US TECH 100
23,604.40
(
-0.81%
)
Dow Jones
45,931.56
(
-0.64%
)
Brent Oil
104.17
(
-2.27%
)
Bitcoin
69,908.23
(
-1.87%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: InTheTrenches post# 83845

Monday, 09/21/2009 7:47:03 AM

Monday, September 21, 2009 7:47:03 AM

Post# of 257259
MNTA:

Given its advantages, wouldn't M-118 mostly replace Lovenox in ACS?

I think it would be more apt to say that M118 has the potential to supersede Angiomax and unfractionated heparin (as well as Lovenox) in ACS. Bear in mind that ACS is a relatively small part of Lovenox’s total sales. Regards, Dew


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now